International validation of AISmartDensity
| Reference number | |
| Coordinator | Karolinska Institutet - Karolinska Institutet Inst f onkologi & patologi |
| Funding from Vinnova | SEK 899 793 |
| Project duration | November 2024 - December 2025 |
| Status | Ongoing |
| Venture | Preparation projects for international application within health |
| Call | Towards deeper collaboration with UK and USA partners within Health and Life Science |
Important results from the project
The project achieved its main goals. AISmartDensity was adapted for different mammography systems, deployed at partner sites, and successfully validated by a U.S. partner. The project also generated important additional results, including new collaborations in the Netherlands, the U.S., and Taiwan, and direct contributions to CE marking, GUIDE-AI, and future international studies.
Expected long term effects
In the long term, the project is expected to enable more accurate and resource-efficient breast cancer screening through internationally validated AI-based risk assessment. It strengthens the pathway toward CE marking, future multicenter studies, and the integration of genetic and imaging-based risk models. Ultimately, this may contribute to earlier detection and fewer late cancer diagnoses globally.
Approach and implementation
The project was carried out as planned, with appropriate activities and a well-functioning international collaboration. AISmartDensity was technically adapted, deployed at partner sites, and validated as intended by a U.S. partner. The timeline was largely followed, no major external obstacles arose, and the collaboration worked well, further strengthened by new international partners.